Maria Jison

机构：AstraZeneca (Spain), AstraZeneca (United States)

发表论文 54 篇 · 总被引 3319 次 · h-index 16

代表论文

• Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial (2024 · European Respiratory Journal · 被引 25)
• Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis (2025 · Annals of the Rheumatic Diseases · 被引 19)
• Effect of benralizumab treatment on the airway microbiome in COPD (2024 · ERJ Open Research · 被引 5)
• Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial (2026 · Nature Medicine · 被引 3)
• BENRALIZUMAB FOR PATIENTS WITH HYPEREOSINOPHILIC SYNDROME: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL (NATRON) (2025 · Annals of Allergy Asthma & Immunology · 被引 3)
• Pharmacodynamic Effects of Benralizumab on Eosinophil-related Biomarkers in COPD: A Biomarker Analysis of the GALATHEA Study (2025 · American Journal of Respiratory and Critical Care Medicine · 被引 2)